"They are aware of a company infringing their patents but it may currently not be worth fighting over, however they mentioned that if cost is not restrictive, they will defend."
See that's a pretty tricky situation aswell considering I'd assume one of the big pharmas key pieces of undertaking due dilligence was to ensure all the IP & patents are firmly locked down & protected, however the company certainly sounds on top of the game without concern & i guess if it was pressing on one of the key areas for a current partner then they would probably contribute to costs if "fighting" over it became essential.
melbourne shareholder briefing, page-4
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.005(2.86%) |
Mkt cap ! $839.8M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.0¢ | $416.7K | 2.381M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 255743 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 809448 | 8 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |